Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals. This is mainly to explore potential cures for diseases that might affect humans. Other purposes of gene editing include making crops more resistant to viruses and bacteria and better able to cope with extremes of heat and cold caused by global warming. One day, gene editing could alter people’s DNA and prevent certain diseases from developing. In some circles, gene editing is controversial, though the science behind it is widely viewed as legitimate. Investors can invest in several biopharmaceutical companies to gain exposure to this cutting-edge and fast-growing area of science. Here are three gene editing stocks that could grow your wealth. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics (CRSP) the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone Source: rafapress / Shutterstock.com Swiss biotech firm Crispr Therapeutics (NASDAQ:CRSP) is one of the first companies in the world to leverage the CRISPR gene editing platform. The platform is widely viewed as the gold standard in developing medicine for treating rare and common diseases. The company’s global manufacturing center is in Boston, and its founder, Emmanuelle Charpentier, won the Nobel Prize in Chemistry in 2020. CRSP stock is a small-cap with a current market capitalization of $5.33 billion. The share price has wobbled, declining 5% this year but gaining 28% over the last five years. The company remains unprofitable 10 years after its founding, but it plans to bring treatments to market for various blood diseases, cancers, diabetes and other illnesses. In time, Crispr Therapeutics stock could take off and become a winner. Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals (VRTX) logo visible on display screen Source: Pavel Kapysh / Shutterstock.com Boston-based Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best gene editing stocks investors can own. It’s certainly been one of the best performers. VRTX stock has gained 19% this year, is up 37% over the past 12 months, and has risen 180% in the last five years. The stock is currently trading near a 52-week high. It also has a hefty market capitalization of $126 billion. Vertex Pharmaceuticals is a more mature and established biotech company than others involved in gene editing, the majority of which are start-ups. A going concern since 1989 and publicly traded since 1991, Vertex brought its first drug to market in 2012, a treatment for the genetic disease Cystic Fibrosis. The company has recently been employing gene editing to treat inflammatory and autoimmune disorders and some cancers. VRTX stock trades at a reasonable valuation of 31 times future earnings estimates. Intellia Therapeutics (NTLA) Intellia Therapeutics (NTLA Stock) logo on a smartphone screen. Source: rafapress / Shutterstock.com Intellia Therapeutics (NASDAQ:NTLA) is another biotech start-up company based in Boston that has been in business for the last decade. It, too, employs the CRISPR gene editing platform to develop disease treatments and medications. Intellia’s scientific founders at the University of California, Berkeley, invented the CRISPR gene editing system. Intellia Therapeutics uses CRISPR to research and potentially find treatments for diseases and hereditary conditions such as Hemophilia and some cancers. NTLA stock can be considered a micro-cap as it currently has a market capitalization of only $2.64 billion. In terms of performance, Intellia Therapeutics’ stock has declined 11% so far in 2024, though it has gained 60% in the past five years. This is another gene editing stock with potential. On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia. More From InvestorPlace Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future” The post 3 Gene Editing Stocks That Could Grow Your Wealth appeared first on InvestorPlace.
3 Gene Editing Stocks That Could Grow Your Wealth
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...